SMi is proud to announce the return the 12th annual Asthma and COPD conference 2016 in London!
Respiratory diseases represent an enormous and increasing healthcare and economic burden across Europe and USA.
Over the last few years, significant improvements in the management of asthma and COPD have been made, owing to new drugs, strategies and to the development of the nonpharmacologic treatment of COPD. Nevertheless, there are still many unmet needs in the treatment of these diseases.
Join us at SMi's 12th annual Asthma and COPD taking place on the 11th - 12th April 2016 in London. This event will explore innovative asthma and COPD drug development programmes, directives and procedures which have been put in place to reduce the enormous suffering from lung disease and its high mortality.
KEYNOTE SPEAKERS INCLUDE:
Peter Daley-Yates, Director Clinical Pharmacology, GSK
Andy Kenwright, Senior Statistical Scientist, Roche Pharma
Jan Olof Svensson, Principle Scientist, Astrazeneca
Roland Kolbeck, Senior Director, MedImmune
Nayna Govind, Director for the Development of Generic
Inhalation Products, Dr. Reddy's Laboratories
Konstantinos Kostikas, Medical Director Respiratory, Novartis
EARLY BIRD OFFERS
Book by 18th December 2015 to receive 拢400 off the conference price
Book by 29th January 2016 to receive 拢200 off the conference price
Book by 29th February 2016 to receive 拢100 off the conference price
For more information visit www.asthma-copd.co.uk/evvnt
Respiratory diseases represent an enormous and increasing healthcare and economic burden across Europe and USA.
Over the last few years, significant improvements in the management of asthma and COPD have been made, owing to new drugs, strategies and to the development of the nonpharmacologic treatment of COPD. Nevertheless, there are still many unmet needs in the treatment of these diseases.
Join us at SMi's 12th annual Asthma and COPD taking place on the 11th - 12th April 2016 in London. This event will explore innovative asthma and COPD drug development programmes, directives and procedures which have been put in place to reduce the enormous suffering from lung disease and its high mortality.
KEYNOTE SPEAKERS INCLUDE:
Peter Daley-Yates, Director Clinical Pharmacology, GSK
Andy Kenwright, Senior Statistical Scientist, Roche Pharma
Jan Olof Svensson, Principle Scientist, Astrazeneca
Roland Kolbeck, Senior Director, MedImmune
Nayna Govind, Director for the Development of Generic
Inhalation Products, Dr. Reddy's Laboratories
Konstantinos Kostikas, Medical Director Respiratory, Novartis
EARLY BIRD OFFERS
Book by 18th December 2015 to receive 拢400 off the conference price
Book by 29th January 2016 to receive 拢200 off the conference price
Book by 29th February 2016 to receive 拢100 off the conference price
For more information visit www.asthma-copd.co.uk/evvnt
